BBV152 prime cohort
diarrhoea, hypertension, pain
EVENTS, EVENT, HYPERTENSION, SEQUELAE
A total of 4 unsolicited AEs in 4 participants (5.4%) were reported in the SII-NVX-CoV2373 group and 6 unsolicited AEs in 5 participants (5.3%) in the BBV152 group. None was treatment-related in the SII-NVX-CoV2373 group and 2 events in the BBV152 group were treatment-related (diarrhoea and injection site pain). All AEs were of mild to moderate severity (except for 1 severe event of hypertension in the BBV152 group) and resolved without any sequelae.There were no AEs which led to study discontinuation. There was only one case of COVID-19 at 3 months after the booster in the BBV152 group which was mild in severity, and resolved without any sequelae.